Shanghai Fosun Pharmaceutical Group Co Ltd - Asset Resilience Ratio

Latest as of March 2026: 1.81%

Shanghai Fosun Pharmaceutical Group Co Ltd (600196) has an Asset Resilience Ratio of 1.81% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Shanghai Fosun Pharmaceutical Group Co L's working capital to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥2.23 Billion
≈ $325.77 Million USD Cash + Short-term Investments

Total Assets

CN¥122.97 Billion
≈ $17.99 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2001–2025)

This chart shows how Shanghai Fosun Pharmaceutical Group Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Shanghai Fosun Pharmaceutical Group Co L's balance sheet.

Liquid Assets Composition Over Time

This chart breaks down Shanghai Fosun Pharmaceutical Group Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore 600196 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥2.23 Billion 1.81%
Total Liquid Assets CN¥2.23 Billion 1.81%

Asset Resilience Insights

  • Limited Liquidity: Shanghai Fosun Pharmaceutical Group Co Ltd maintains only 1.81% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Shanghai Fosun Pharmaceutical Group Co Ltd Industry Peers by Asset Resilience Ratio

Compare Shanghai Fosun Pharmaceutical Group Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Torrent Pharmaceuticals Limited
NSE:TORNTPHARM
Drug Manufacturers - Specialty & Generic 2.79%
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
Drug Manufacturers - Specialty & Generic 1.54%
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Drug Manufacturers - Specialty & Generic 0.20%
Beijing Tongrentang Co Ltd
SHG:600085
Drug Manufacturers - Specialty & Generic 2.51%
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
Drug Manufacturers - Specialty & Generic 3.47%
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423
Drug Manufacturers - Specialty & Generic 20.44%
Harbin Pharmaceutical Group Co Ltd
SHG:600664
Drug Manufacturers - Specialty & Generic 0.97%
Kangmei Pharmaceutical Co Ltd
SHG:600518
Drug Manufacturers - Specialty & Generic 0.00%

Annual Asset Resilience Ratio for Shanghai Fosun Pharmaceutical Group Co Ltd (2001–2025)

The table below shows the annual Asset Resilience Ratio data for Shanghai Fosun Pharmaceutical Group Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 4.97% CN¥5.99 Billion
≈ $875.80 Million
CN¥120.47 Billion
≈ $17.63 Billion
+2.76pp
2024-12-31 2.21% CN¥2.60 Billion
≈ $379.88 Million
CN¥117.46 Billion
≈ $17.19 Billion
+0.55pp
2023-12-31 1.66% CN¥1.89 Billion
≈ $276.35 Million
CN¥113.47 Billion
≈ $16.60 Billion
+0.80pp
2022-12-31 0.87% CN¥928.53 Million
≈ $135.87 Million
CN¥107.16 Billion
≈ $15.68 Billion
-3.68pp
2021-12-31 4.55% CN¥4.24 Billion
≈ $620.60 Million
CN¥93.29 Billion
≈ $13.65 Billion
+2.19pp
2020-12-31 2.35% CN¥1.97 Billion
≈ $288.29 Million
CN¥83.69 Billion
≈ $12.25 Billion
+1.75pp
2019-12-31 0.60% CN¥456.65 Million
≈ $66.82 Million
CN¥76.12 Billion
≈ $11.14 Billion
-0.27pp
2018-12-31 0.87% CN¥616.12 Million
≈ $90.16 Million
CN¥70.55 Billion
≈ $10.32 Billion
+0.52pp
2017-12-31 0.35% CN¥219.33 Million
≈ $32.09 Million
CN¥61.97 Billion
≈ $9.07 Billion
+0.24pp
2016-12-31 0.11% CN¥48.49 Million
≈ $7.10 Million
CN¥43.77 Billion
≈ $6.40 Billion
+0.02pp
2015-12-31 0.09% CN¥33.75 Million
≈ $4.94 Million
CN¥38.20 Billion
≈ $5.59 Billion
-0.01pp
2014-12-31 0.10% CN¥33.77 Million
≈ $4.94 Million
CN¥35.34 Billion
≈ $5.17 Billion
-0.05pp
2013-12-31 0.15% CN¥44.20 Million
≈ $6.47 Million
CN¥29.48 Billion
≈ $4.31 Billion
-0.73pp
2012-12-31 0.88% CN¥224.83 Million
≈ $32.90 Million
CN¥25.51 Billion
≈ $3.73 Billion
-0.16pp
2011-12-31 1.04% CN¥231.32 Million
≈ $33.85 Million
CN¥22.29 Billion
≈ $3.26 Billion
-0.26pp
2010-12-31 1.30% CN¥218.76 Million
≈ $32.01 Million
CN¥16.82 Billion
≈ $2.46 Billion
+1.20pp
2009-12-31 0.10% CN¥11.70 Million
≈ $1.71 Million
CN¥11.53 Billion
≈ $1.69 Billion
+0.10pp
2008-12-31 0.00% CN¥94.32K
≈ $13.80K
CN¥7.54 Billion
≈ $1.10 Billion
-0.08pp
2007-12-31 0.08% CN¥5.84 Million
≈ $855.13K
CN¥7.43 Billion
≈ $1.09 Billion
+0.05pp
2006-12-31 0.03% CN¥2.11 Million
≈ $309.12K
CN¥6.63 Billion
≈ $970.75 Million
-0.07pp
2004-12-31 0.10% CN¥5.20 Million
≈ $760.92K
CN¥5.17 Billion
≈ $756.61 Million
+0.10pp
2003-12-31 0.00% CN¥200.00K
≈ $29.27K
CN¥4.22 Billion
≈ $617.35 Million
-9.08pp
2002-12-31 9.09% CN¥285.35 Million
≈ $41.76 Million
CN¥3.14 Billion
≈ $459.42 Million
+9.05pp
2001-12-31 0.04% CN¥871.98K
≈ $127.60K
CN¥2.21 Billion
≈ $323.00 Million
--
pp = percentage points

About Shanghai Fosun Pharmaceutical Group Co Ltd

SHG:600196 China Drug Manufacturers - Specialty & Generic
Market Cap
$7.17 Billion
CN¥49.00 Billion CNY
Market Cap Rank
#2855 Global
#353 in China
Share Price
CN¥23.13
Change (1 day)
+0.35%
52-Week Range
CN¥21.21 - CN¥30.34
All Time High
CN¥85.06
About

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumor… Read more